Optimizing factor prophylaxis for the haemophilia population: Where do we stand?

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 97-104

  Blanchette, Victor S ^a   Manco Johnson, M ^b   Santagostino, E ^c   Ljung, R ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Haemophilia; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR;

AGE; ARTERIOVENOUS FISTULA; ARTHRITIS; ARTHROPATHY; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; CATHETER INFECTION; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; HEALTH CARE ACCESS; HEALTH PROGRAM; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; JOINT DESTRUCTION; LONG TERM CARE; MUSCULOSKELETAL DISEASE; ONSET AGE; PATIENT COMPLIANCE; PERIPHERAL VEIN; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SUBSTITUTION THERAPY; SWEDEN; THROMBOSIS; VASCULAR ACCESS;

EID: 11044219714     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00998.x     Document Type: Article

References (38)

1. Mannucci PM, Tuddenham EGD. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. BMJ 1979; 1: 469-70.
3. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
4. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
5. Ahlberg Å. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of hemophilia A and B. Acta Orthop Scand 1965; 77 (Suppl. 1): 7-80.
6. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32.
7. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Hemophilic prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
8. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe hemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
9. Blanchette VS. Prophylaxis in hemophilia: a comprehensive perspective. Haematologica 2004; 89 (Suppl. 1): 29-35.
10. Ljung RCR. Prophylactic treatment in Sweden - over-treatment or optimal model? Haemophilia 1998; 4: 409-12.
11. Pettersson H, Gilbert M. Diagnostic imaging in hemophilia: Musculoskeletal and other hemorrhagic complications. Berlin, Heidelberg: Springer-Verlag 1985; 56-65.
12. Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149 153-9.
13. Aledort LM, Haschmeyer RH, Pettersson H, and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophliacs. J Intern Med 1994; 236: 391-9.
14. MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC recommendation 117, June 2001.
15. Ljung RCR. Can haemophilic arthopathy be prevented? Br J Haematol 1998; 101: 215-9.
16. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004; 18: 101-13.
17. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
18. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
19. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
20. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
21. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 3): S166-70.
22. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
23. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
24. Feldman B, Rivard G, Israel S, Dagger S et al. Final results of the Canadian hemophilia dose escalation prophylaxis trial. J Thromb Haemost 2003; 1 (Suppl. 1): OC219 (Abstract).
25. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.
26. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998; 87: 1051-4.
27. Ljung R. Central venous catheters in children with hemophilia. Blood Rev 2004; 18: 93-100.
28. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
29. Price VE, Carcao M, Connolly B et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 1-6.
30. Santagostino E, Gringeri A, Muça-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1224-8.
31. Santagostina E, Gringeri A, Berardinelli L, Beretta C, Muça-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003; 123: 502-6.
32. Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
33. von Mackenson S, Bullinger M, the HaemoQoL Group. Development and testing of an instrument to assess the quality of life of children with hemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10 Suppl. 1): 17-25.
34. Young NL, Bradley CS, Blanchette V, Wakefield C, Barnard D, McCusker PJ. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT). Haemophilia 2004; 10 (Suppl. 1 : 1-10.
35. Bohn RL, Avorn J, Glynn RJ, Choodnovsky I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
36. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A. A cost-effectiveness analysis. J Pediatr 1996; 129: 421-31.
37. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
38. Fischer K, Astermark J, van der Bom Ljung R, Berntorp E, Grobbee DE, van den Berg HM. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.